Haemostatic effects of stanozolol in elderly medical patients.
D000368:Aged; D000990:Antithrombin III / Q000032:analysis; D005260:Female; D005340:Fibrinogen / Q000032:analysis; D005343:Fibrinolytic Agents / Q000494:pharmacology*; D006023:Glycoproteins / Q000097:blood; D006487:Hemostasis / Q000187:drug effects*; D006801:Humans; D008111:Liver Function Tests; D008297:Male; D008875:Middle Aged; D010958:Plasminogen / Q000032:analysis; D010960:Plasminogen Activators / Q000032:analysis; D011486:Protein C; D013197:Stanozolol / Q000494:pharmacology*; D000979:alpha-2-Antiplasmin / Q000032:analysis
D005343:Fibrinolytic Agents; D006023:Glycoproteins; D011486:Protein C; D000979:alpha-2-Antiplasmin; D013197:Stanozolol; D000990:Antithrombin III; D005340:Fibrinogen; D010958:Plasminogen; D010960:Plasminogen Activators